导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.92% | 1476/4773 |
| 近一周 | -2.49% | 2337/5462 |
| 近一月 | -4.79% | 2752/5421 |
| 近一季 | -8.62% | 2883/5209 |
| 近半年 | -6.12% | 3017/4920 |
| 近一年 | 7.96% | 1238/4366 |
| 近两年 | 69.42% | 986/2954 |
| 近三年 | 36.54% | 819/2253 |
| 成立以来 | 93.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.88% 1146/4961 |
18.63% 1360/5312 |
- - |
- - |
| 2025 | 30.79% 1289/4813 |
2.03% 1488/3635 |
1.87% 2062/4076 |
24.46% 1466/4524 |
1.10% 1536/4813 |
| 2024 | 6.35% 1770/3463 |
-2.36% 1354/2808 |
-4.98% 1605/3014 |
15.93% 1589/3129 |
-1.12% 1596/3463 |
| 2023 | -5.67% 762/2656 |
7.54% 558/2280 |
-4.02% 1015/2385 |
-4.39% 1131/2515 |
-4.42% 1021/2655 |
| 2022 | -18.21% 676/2207 |
-13.51% 769/1919 |
2.73% 1266/2016 |
-10.41% 398/2113 |
2.75% 844/2208 |
| 2021 | 17.01% 251/1822 |
-1.32% 466/1255 |
9.68% 532/1330 |
4.52% 343/1466 |
3.43% 433/1822 |
| 2020 | 22.13% 675/1250 |
-3.82% 323/1028 |
16.17% 454/1067 |
6.16% 868/1164 |
2.96% 950/1184 |
| 2019 | 24.58% 614/1092 |
30.06% 260/754 |
-9.62% 673/804 |
0.17% 552/850 |
5.80% 671/918 |
| 2018 | -30.52% 471/834 |
- - |
- - |
- - |
-12.14% 406/691 |
| 2017 | 0.90% 462/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.14% 372/605 |
- - |
- - |
- - |
- - |
| 2015 | 35.58% 60/575 |
- - |
- - |
- - |
- - |
| 2014 | 35.10% 147/237 |
- - |
- - |
- - |
- - |
| 2013 | 15.76% 24/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.14% 117/140 |
- - |
- - |
- - |
- - |
| 2011 | -32.51% 96/102 |
- - |
- - |
- - |
- - |
| 2010 | 8.52% 5/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证500ETF联接A VS. 长安沪深300非周期A(740101) |